uniQure's Gene Therapy Shows Early Promise in Refractory Epilepsy Trial
Event summary
- Three of six patients in the low-dose cohort of uniQure's Phase I/IIa trial for AMT-260 showed 79% to 100% reduction in disabling seizures.
- No serious adverse events related to AMT-260 or the surgical procedure were reported.
- Enrollment in the higher dose cohort (3x1012 gc/mL) is ongoing, with completion expected mid-2026.
- Updated results from the Phase I/IIa clinical trial are anticipated in the first half of 2027.
The big picture
uniQure's AMT-260 represents a novel approach to treating refractory mesial temporal lobe epilepsy, a condition affecting approximately 300,000 people in the U.S. who are inadequately treated by current anti-seizure medications. The early biological signals of activity, coupled with a favorable safety profile, position uniQure to potentially disrupt the epilepsy treatment landscape, which has seen limited therapeutic advancements in recent years. The success of AMT-260 could also bolster uniQure's pipeline and strategic positioning in the gene therapy space.
What we're watching
- Dose Response
- Whether the higher dose cohort will show more consistent or pronounced seizure reduction.
- Safety Profile
- How the safety and tolerability of AMT-260 will be maintained as the trial progresses.
- Regulatory Pathway
- The pace at which uniQure can advance AMT-260 through subsequent clinical phases and potential approval.
Related topics